Developers invest more to explore full potential of CAR-T therapies

10 January 2024

biotech_lab_research_vial_manufacturing_big

New York-based TG Therapeutics (Nasdaq: TGTX) has entered into an agreement with Precision BioSciences (Nasdaq: DTIL) related to an allogeneic CD19 CAR-T cell therapy.

TG has an established record in the multiple sclerosis space, most notably with Briumvi (ublituximab-xiiy), which is approved in the USA for relapsing forms of the condition.

The company is not alone in paying more attention to the potential of cell therapies in autoimmune diseases, with CAR-T specialist Allogene Therapeutics (Nasdaq: ALLO) recently announcing new plans, including a program in lupus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK